Nautilus Biotechnology initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Nautilus Biotechnology with a Buy rating and $6 price target. The analyst says the company has an innovative platform for proteome analysis and discovery applications. The company’s platform addresses the limitations of existing protein analysis technologies with high-throughput capabilities and unique discovery use cases, the analyst tells investors in a research note. The firm believes Nautilus’ technology fills a market need for new proteome analysis tools.